CA2341855A1 - Method for treating schizophrenia, and means for use in this method - Google Patents

Method for treating schizophrenia, and means for use in this method Download PDF

Info

Publication number
CA2341855A1
CA2341855A1 CA002341855A CA2341855A CA2341855A1 CA 2341855 A1 CA2341855 A1 CA 2341855A1 CA 002341855 A CA002341855 A CA 002341855A CA 2341855 A CA2341855 A CA 2341855A CA 2341855 A1 CA2341855 A1 CA 2341855A1
Authority
CA
Canada
Prior art keywords
nicotine
pharmaceutically acceptable
acceptable salt
medical device
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002341855A
Other languages
English (en)
French (fr)
Inventor
Reinhold Meconi
Volker Siemund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2341855A1 publication Critical patent/CA2341855A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
CA002341855A 1998-10-16 1999-10-02 Method for treating schizophrenia, and means for use in this method Abandoned CA2341855A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19847715A DE19847715A1 (de) 1998-10-16 1998-10-16 Verfahren zur Behandlung der Schizophrenie sowie Mittel zur Verwendung in diesem Verfahren
DE19847715.5 1998-10-16
PCT/EP1999/007320 WO2000023077A1 (de) 1998-10-16 1999-10-02 Verfahren zur behandlung der schizophrenie sowie mittel zur verwendung in diesem verfahren

Publications (1)

Publication Number Publication Date
CA2341855A1 true CA2341855A1 (en) 2000-04-27

Family

ID=7884666

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002341855A Abandoned CA2341855A1 (en) 1998-10-16 1999-10-02 Method for treating schizophrenia, and means for use in this method

Country Status (10)

Country Link
EP (1) EP1121126A1 (ko)
JP (1) JP2002527478A (ko)
KR (1) KR20010080135A (ko)
CN (1) CN1323210A (ko)
AR (1) AR020815A1 (ko)
AU (1) AU6199299A (ko)
BR (1) BR9914570A (ko)
CA (1) CA2341855A1 (ko)
DE (1) DE19847715A1 (ko)
WO (1) WO2000023077A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10110953A1 (de) * 2001-03-07 2002-09-19 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von partiellen Dopamin-D2-Agonisten
KR20060120156A (ko) * 2003-10-28 2006-11-24 알자 코포레이션 담배의 이용빈도를 감소시키기 위한 방법 및 장치
IL177071A0 (en) * 2005-08-01 2006-12-10 Nitto Denko Corp Method of preparing a nicotine transdermal preparation
WO2012154710A1 (en) * 2011-05-09 2012-11-15 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with nicotine
CZ309812B6 (cs) * 2021-05-25 2023-11-01 Consumer Brands International s.r.o Směs pro výrobu nikotinových sáčků a způsob její výroby

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4915950A (en) * 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
US5776956A (en) * 1996-07-30 1998-07-07 Lectec Corporation Use of cotinine in treating psychiatric disorders
US5776957A (en) * 1996-11-15 1998-07-07 The University Of Kentucky Research Foundation Nornicotine enantiomers for use as a treatment for dopamine related conditions and disease states

Also Published As

Publication number Publication date
AR020815A1 (es) 2002-05-29
KR20010080135A (ko) 2001-08-22
BR9914570A (pt) 2001-07-03
EP1121126A1 (de) 2001-08-08
CN1323210A (zh) 2001-11-21
AU6199299A (en) 2000-05-08
WO2000023077A1 (de) 2000-04-27
DE19847715A1 (de) 2000-04-20
JP2002527478A (ja) 2002-08-27

Similar Documents

Publication Publication Date Title
AU660336B2 (en) Device for the transdermal administration of melatonin
Lehmann et al. Transdermal fentanyl: clinical pharmacology
Sack et al. Use of melatonin for sleep and circadian rhythm disorders
NO20120563L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
JPH07165566A (ja) 極少量の薬剤の投与のための医療用品
NO954925D0 (no) Metode for behandling av smerte ved administrering av 24 timers orale opioidformuleringer som utviser hurtig stigningsgrad av plasmalegemiddelnivå
HK1081436A1 (en) Hot melt tts for administering rotigotine
Letechipı́a-Vallejo et al. Neuroprotective effect of melatonin on brain damage induced by acute global cerebral ischemia in cats
CA2530005C (en) Use of buprenorphine for the treatment of drug dependence withdrawal in a pregnant woman
CA2341855A1 (en) Method for treating schizophrenia, and means for use in this method
KR101000624B1 (ko) 멜라토닌을 포함하는 약제학적 제제
Lal et al. Apomorphine and psychopathology.
CA2168882A1 (en) Therapeutic system for treating psoriasis
US6143320A (en) Method for the application of an active substance patch for controlling or alleviating an addiction
DE19850517B4 (de) Verwendung eines wirkstoffhaltigen transdermalen therapeutischen Systems in einer Kombinationsbehandlung mit und ohne Ultraschall
WO2002047688A2 (en) Method and apparatus for treating breakthrough pain
US20220040120A1 (en) Pharmaceutical formulations containing gaboxadol for therapeutic treatment
CN110548132A (zh) TGF-β1蛋白在制备治疗抑郁症的药物中的应用
US20070265238A1 (en) Method for accelerating reentrainment of a circadian rhythm
KR20000029523A (ko) 치매치료및(또는)예방용제제
Dose et al. Calcium antagonists in mania: a preliminary clinical report
WO2002083135A2 (en) Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
KR20050032590A (ko) 알코올 및/또는 담배 소비 감소를 위한 의약 및 방법
KR20070085036A (ko) 정신분열성 정신병 치료를 위한 데옥시페가닌의 용도
MXPA99007798A (en) Sustained analgesia achieved with buprenorphine

Legal Events

Date Code Title Description
FZDE Dead